Cognition Therapeutics
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2500 Westchester Ave, Purchase, New York...Phone Number
(412) 481-2210Website
www.cogrx.comRevenue
$5.3 MillionStock Symbol
CGTXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Cognition Therapeutics
Cognition Therapeutics is a clinical stage biopharmaceutical company developing small-molecule therapeutics that address the toxic oligomeric proteins that cause synapse degeneration and trigger neurodegenerative conditions such as Alzheimer's disease.Explore more
Cognition Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cognition Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Cognition Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Cognition Therapeutics launches new products
Earning: See what the market has to say on Cognition Therapeutics recently announced quarterly report
Click to see if Cognition Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Cognition Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Cognition Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Cognition Therapeutics has new funding data
Cognition Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Cognition Therapeutics
Compare insights from companies similar to Cognition Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cognition Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cognition Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cognition Therapeutics.
Cognition Therapeutics financials insights
Gather financial insights about Cognition Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Debt
$3M
2013
Unspecified
$138K
2014
Private Equity
$15.8M
2015
Series B
$12M
2016
Debt
$3.5M
Private Equity
$4.2M
2020
Debt
$350K
2021
Debt
$435K
Cognition Therapeutics Tech Stack
A closer look at the technologies used by Cognition Therapeutics
Most Recent Scoops
Person-Based
Intellectual Property, Legal Affairs
Project
Cognition Therapeutics has identified key value inflection points for its zervimesine program, including receipt of formal FDA meeting minutes defining the registrational pathway for DLB, operational milestones such as CRO identification and first patient enrollment, and results from the START program that will inform a potential Phase III registrational program in Alzheimer's disease.
Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Cognition Therapeutics has announced a strategic focus on the psychosis indication specifically hallucinations and delusions for its DLB program, citing the strength of the data and the potential for a smaller, faster, and more cost-efficient registrational trial compared to broader indication studies.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Clinical Operations
Cognition Therapeutics News & Media
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.Cognition Therapeutics Participating in Upcoming Investor Conferences
PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at two financial conferences in June, where she will provide updates on the Company’s plans for a registration program in DLB psychosis. Live and archived webcasts of Ms. Ricciardi's presentations will be available on the Investor RelationsCognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
- Positive Discussion on Path Forward for Registrational Program -
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Cognition Therapeutics
Sign Up For FreeTo access detailed company insights
Cognition Therapeutics is a clinical stage biopharmaceutical company developing small-molecule therapeutics that address the toxic oligomeric proteins that cause synapse degeneration and trigger neurodegenerative conditions such as Alzheimer's disease.... Read More
